DK3412671T3 - TLR7-agonist-maleatsalt, krystallinske former C, D og E deraf, fremgangsmåder til fremstilling og anvendelser af maleatsalt og krystallinske former - Google Patents
TLR7-agonist-maleatsalt, krystallinske former C, D og E deraf, fremgangsmåder til fremstilling og anvendelser af maleatsalt og krystallinske former Download PDFInfo
- Publication number
- DK3412671T3 DK3412671T3 DK17747003.6T DK17747003T DK3412671T3 DK 3412671 T3 DK3412671 T3 DK 3412671T3 DK 17747003 T DK17747003 T DK 17747003T DK 3412671 T3 DK3412671 T3 DK 3412671T3
- Authority
- DK
- Denmark
- Prior art keywords
- crystalline forms
- maleate salt
- processes
- preparation
- tlr7 agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610082030.0A CN107043380A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
PCT/CN2017/072890 WO2017133683A1 (zh) | 2016-02-05 | 2017-02-04 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3412671T3 true DK3412671T3 (da) | 2020-11-09 |
Family
ID=59500111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17747003.6T DK3412671T3 (da) | 2016-02-05 | 2017-02-04 | TLR7-agonist-maleatsalt, krystallinske former C, D og E deraf, fremgangsmåder til fremstilling og anvendelser af maleatsalt og krystallinske former |
Country Status (24)
Country | Link |
---|---|
US (2) | US10780091B2 (da) |
EP (1) | EP3412671B1 (da) |
JP (1) | JP6898336B2 (da) |
KR (1) | KR102393279B1 (da) |
CN (2) | CN107043380A (da) |
AR (1) | AR107547A1 (da) |
AU (1) | AU2017215800B2 (da) |
CA (1) | CA3013682C (da) |
CL (1) | CL2018002089A1 (da) |
DK (1) | DK3412671T3 (da) |
EA (1) | EA038794B1 (da) |
ES (1) | ES2834303T3 (da) |
HK (1) | HK1259175A1 (da) |
HU (1) | HUE052211T2 (da) |
IL (1) | IL260965B (da) |
MX (1) | MX2018009500A (da) |
MY (1) | MY196762A (da) |
NZ (1) | NZ745231A (da) |
PH (1) | PH12018501644A1 (da) |
SG (1) | SG11201806682TA (da) |
TW (1) | TWI778951B (da) |
UA (1) | UA123781C2 (da) |
WO (1) | WO2017133683A1 (da) |
ZA (1) | ZA201805185B (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
CN107043379A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
KR20210013183A (ko) * | 2018-05-25 | 2021-02-03 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Tlr7 작용제 및 폐암을 치료하기 위한 이의 약학 조합물 |
WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
US20230100429A1 (en) | 2020-03-02 | 2023-03-30 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
WO2022031021A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신 |
CN116056725A (zh) | 2020-08-04 | 2023-05-02 | 蛋白科技先鋒 | 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途 |
JP2023536945A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 動力学的に作用するアジュバントアンサンブル |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
WO1998001448A1 (fr) | 1996-07-03 | 1998-01-15 | Japan Energy Corporation | Nouveaux derives de purine |
NZ504800A (en) | 1997-11-28 | 2001-10-26 | Sumitomo Pharma | 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof |
JP2009504803A (ja) | 2005-08-22 | 2009-02-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Tlrアゴニスト |
TWI434849B (zh) | 2007-06-29 | 2014-04-21 | Gilead Sciences Inc | 類鐸(Toll-like)受體7之調節劑 |
CA2707030A1 (en) | 2007-08-03 | 2009-02-12 | Pfizer Limited | Imidazopyridinones |
EA021377B9 (ru) | 2008-12-09 | 2015-09-30 | Джилид Сайэнс, Инк. | Модуляторы толл-подобных рецепторов |
EP2670244B1 (en) | 2011-02-04 | 2018-04-11 | Duquesne University of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
EP2800569B1 (en) | 2012-01-05 | 2018-07-25 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
NZ705589A (en) * | 2012-10-10 | 2019-05-31 | Janssen Sciences Ireland Uc | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
EP2922550B1 (en) | 2012-11-20 | 2017-04-19 | Glaxosmithkline LLC | Novel compounds |
WO2014081645A1 (en) | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
KR20150085081A (ko) | 2012-11-20 | 2015-07-22 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
JP6452711B2 (ja) | 2014-02-20 | 2019-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | ヒトインターフェロンの誘導物質としてのピロロ[3,2]ピリミジン誘導体 |
CR20160512A (es) | 2014-05-01 | 2016-12-21 | Novartis Ag | Compuestos y composiciones como agonistas del receptor tipo toll 7 |
NZ724878A (en) * | 2014-05-01 | 2019-03-29 | Novartis Ag | Compounds and compositions as toll-like receptor 7 agonists |
EA032824B1 (ru) | 2014-08-15 | 2019-07-31 | Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 |
CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
PE20181453A1 (es) | 2015-11-05 | 2018-09-12 | Basf Se | Oxadiazoles sustituidos para combatir hongos fitopatogenos |
EA035116B1 (ru) | 2015-11-05 | 2020-04-29 | Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. | 7-(тиазол-5-ил)пирролопиримидин в качестве агониста рецептора tlr7 |
TWI714661B (zh) | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
CN107043377A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
CN107043379A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
CN107043378A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
-
2016
- 2016-02-05 CN CN201610082030.0A patent/CN107043380A/zh active Pending
-
2017
- 2017-02-03 TW TW106103694A patent/TWI778951B/zh active
- 2017-02-04 MY MYPI2018702706A patent/MY196762A/en unknown
- 2017-02-04 NZ NZ745231A patent/NZ745231A/en unknown
- 2017-02-04 WO PCT/CN2017/072890 patent/WO2017133683A1/zh active Application Filing
- 2017-02-04 ES ES17747003T patent/ES2834303T3/es active Active
- 2017-02-04 KR KR1020187024626A patent/KR102393279B1/ko active IP Right Grant
- 2017-02-04 AU AU2017215800A patent/AU2017215800B2/en active Active
- 2017-02-04 MX MX2018009500A patent/MX2018009500A/es active IP Right Grant
- 2017-02-04 HU HUE17747003A patent/HUE052211T2/hu unknown
- 2017-02-04 DK DK17747003.6T patent/DK3412671T3/da active
- 2017-02-04 CN CN201780009746.0A patent/CN108602830B/zh active Active
- 2017-02-04 JP JP2018540750A patent/JP6898336B2/ja active Active
- 2017-02-04 CA CA3013682A patent/CA3013682C/en active Active
- 2017-02-04 EP EP17747003.6A patent/EP3412671B1/en active Active
- 2017-02-04 UA UAA201809085A patent/UA123781C2/uk unknown
- 2017-02-04 SG SG11201806682TA patent/SG11201806682TA/en unknown
- 2017-02-04 EA EA201891770A patent/EA038794B1/ru unknown
- 2017-02-04 US US16/075,080 patent/US10780091B2/en active Active
- 2017-02-06 AR ARP170100296A patent/AR107547A1/es active IP Right Grant
-
2018
- 2018-08-01 ZA ZA2018/05185A patent/ZA201805185B/en unknown
- 2018-08-02 IL IL260965A patent/IL260965B/en unknown
- 2018-08-02 PH PH12018501644A patent/PH12018501644A1/en unknown
- 2018-08-03 CL CL2018002089A patent/CL2018002089A1/es unknown
-
2019
- 2019-01-24 HK HK19101224.5A patent/HK1259175A1/zh unknown
-
2020
- 2020-08-12 US US16/991,639 patent/US20200368241A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3412671T3 (da) | TLR7-agonist-maleatsalt, krystallinske former C, D og E deraf, fremgangsmåder til fremstilling og anvendelser af maleatsalt og krystallinske former | |
DK3407888T3 (da) | Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser | |
DK3286181T3 (da) | Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne | |
HK1251546A1 (zh) | S-氯胺酮的(s)-csa鹽、s-氯胺酮的(r)-csa鹽和用於製備s-氯胺酮的方法 | |
DK3376859T3 (da) | Mikroorganismer til fremstilling af insektferomoner og relaterede forbindelser | |
DK3497081T3 (da) | Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte | |
DK3262008T3 (da) | Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed | |
DK3668851T3 (da) | Fremgangsmåde til fremstilling af thiocarbonater | |
DK3294865T3 (da) | Fremgangsmåder til fremstilling af epimeraser og benzylisoquinolinalkaloider | |
DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
DK3355329T3 (da) | Metode til fremstilling af lithium-ion-kondensator og kondensator som opnås med den nævnte metode | |
DK3429998T3 (da) | Fremgangsmåde til fremstilling af quinolin-2-yl-phenylaminderivater og disses salte | |
DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
DK3412674T3 (da) | Trifluoracetatsalt af en TLR7-agonist og krystalform B deraf, fremstillingsfremgangsmåder og anvendelser | |
DK3307675T3 (da) | Multi-tryk-fremgangsmåde til fremstilling af ammoniak | |
DK3750893T3 (da) | Dioxazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf | |
DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
DK3460102T3 (da) | Fremgangsmåde til fremstilling af en elektrokatalysator | |
DK3218351T3 (da) | Fremgangsmåde til fremstilling, isolering og oprensning af farmaceutisk anvendelige former af ahu-377 | |
DK3275883T3 (da) | Fremgangsmåde til produktion af ny nitrogenholdig forbindelse eller salt deraf, og mellemprodukt deraf | |
DK3390407T3 (da) | Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser | |
PL3428159T3 (pl) | Postacie krystaliczne soli mesylanowej pochodnej pirydynyloaminopirymidyny, sposoby ich wytwarzania i ich zastosowania | |
DK3560925T3 (da) | Hidtil ukendt forbindelse og farmaceutisk acceptabelt salt deraf | |
DK3634968T3 (da) | Heterocykliske forbindelser, der kan anvendes som antibakterielle midler, og fremgangsmåde til fremstilling heraf | |
DK3248981T3 (da) | C14-hydroxyl-forestrede aminosyrederivater af triptolid, og fremstillingsfremgangsmåde og anvendelse deraf |